Novartis AG ADR (NVS)vsTriSalus Life Sciences Inc. (TLSI)
NVS
Novartis AG ADR
$159.26
+3.59%
HEALTHCARE · Cap: $303.67B
TLSI
TriSalus Life Sciences Inc.
$3.89
+11.78%
HEALTHCARE · Cap: $233.98M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 127158% more annual revenue ($57.36B vs $45.08M). NVS leads profitability with a 17.5% profit margin vs -62.6%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
TLSI
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$159.26
$63.70 premium
Intrinsic value data unavailable for TLSI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
1.7% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 35.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : TLSI
TLSI has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : TLSI
The primary concerns for TLSI are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 5.26 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while TLSI is a turnaround play — different risk/reward profiles.
TLSI carries more volatility with a beta of 0.47 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 18/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →TriSalus Life Sciences Inc.
HEALTHCARE · MEDICAL DEVICES · USA
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical firm at the forefront of enhancing cancer therapy through its proprietary localized drug delivery systems, which significantly improve the effectiveness of immuno-oncology agents. The company is strategically addressing the complexities of tumor microenvironments with a robust pipeline of clinical programs aimed at advancing treatment options in oncology. With a commitment to expanding patient access to transformative therapies, TriSalus is well-positioned to drive meaningful change in cancer care, aligning with the growing demand for advanced, effective cancer treatments. The company’s initiatives underscore its potential to be a key player in the rapidly evolving oncology landscape, attracting interest from both investors and healthcare stakeholders.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?